Articles On Paradigm Biopharmaceuticals (ASX:PAR)

New clinical trial data shows that its trial drug Zilosul (iPPS) also reduces knee cartilage degradation.

Paradigm Biopharmaceuticals (ASX: PAR) has reported a breakthrough in its Phase 2 clinical trial of the injectable pentosan polysulfate (iPPS) treatment drug Zilosul, showing it could act as a cartilage-protective agent and slow cartilage d...

The Australian health system is tagged amongst the best in the world and focusses on providing safe and affordable health care for all the Australians. The federal, state and local government jointly run the system to ensure its adherence....

The Opthea Ltd (ASX: OPT) share price has rocketed 130% to $2.02 this morning after it reported its OPT-302 combination therapy met the primary endpoint in a Phase 2b clinical trial.  According to the announcement the: “OPT-302 + Lucentis...

Medical company Paradigm Biopharmaceuticals (ASX: PAR) has set the stage for a speedy entry into the US after filing its first investigational new drug (IND) submission to the US FDA for an “expanded access program”, that could see as many...

ZilosulÒ (iPPS) is a potential first-line therapeutic treatment for osteoarthritis and other diseases affecting the musculoskeletal system.

Opthea (ASX: OPT) shares have more than doubled this morning after announcing its Phase IIb clinical trial was a success. The 366-patient study tested its OPT-302 drug, which battles wet (neovascular) age-related macular degeneration (AMD)...

Ever since its 2018 initial public offering the Telix Pharmaceuticals Ltd (ASX: TLX) share price has been on a tear as investors buy into its mission to treat brain, kidney and prostate cancers via targeted molecular radiation therapy.  Be...

The healthcare industry in Australia has witnessed rapid developments over the past several years. Thanks to the same, today Australia boasts one of the best healthcare systems in the world. The publicly listed healthcare companies in Austr...

The local biotech sector is fall of landmines able to blow up your capital at any time as most biotech businesses still at the clinical trial stage have no sales revenue and huge clinical trial research costs with no guarantee of ever comm...

The Next Science Ltd (ASX: NXS) share price has more than tripled to $3.09 since its April 2019 initial public offering at $1 per share. Today the group reported an operating cash loss of US$3.43 million on revenue of US$1.2 million for th...

Money Talks is Stockhead’s regular drill down into what stocks investors are looking at right now. We’ll tap our extensive list of experts to see what’s hot, their top picks and what they’re looking out for. Today, we hear from Tom Lambeth,...

At the start of the year James Chisholm’s stake in Atrum Coal (ASX:ATU) was just under $4m. But he’s retired from the board and sold his shares to Regal Funds Management, which now holds 13.5 per cent of the company. With Atrum’s rise from...

Non-executive director Chris Fullerton participated in a $26.3 million entitlement offer and has also purchased shares on-market.

To facilitate its ongoing development and growth, the company signed employment agreements with five new staff members in late June.

The Australian economy, like many countries, is facing challenges in terms of an ageing population, rising chronic diseases, rising demand for new treatments and more hospital beds. S&P/ASX 200 Health Care Index generated an annual retu...

The company is focused on creating commercial opportunities that will generate potential revenue from early sales of finished product or through partnering/commercial transactions.

In this week's Weekly Insights (published in two parts):-Crucial Question: Is It 1995 or 2007?-Conviction Calls -Gold Stocks: Winners & Losers-Rudi On Tour -Rudi TalksConviction Calls By Rudi Filapek-Vandyck, Editor FNArena Stockb...

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...